Aa
weight based????
hi all, just a quick question. i took my 2nd shot las nite and still no sides or any probs 2 worry bout,
im 3a and on 180 peg and 800 riba, i weigh 90.8kg and my hb was 16.2 on thursday.
i jus want 2 know how do i go about getting doc 2 up my riba?
i mentioned it 2 the nurse b4 i seen the doc on thurs and she started talking bout a weight based injection????
its jus that i really want 2 beat it this time around and i feel if i can handle it would be 2 up my riba.
please all ur thoughts are needed.
wayne
im 3a and on 180 peg and 800 riba, i weigh 90.8kg and my hb was 16.2 on thursday.
i jus want 2 know how do i go about getting doc 2 up my riba?
i mentioned it 2 the nurse b4 i seen the doc on thurs and she started talking bout a weight based injection????
its jus that i really want 2 beat it this time around and i feel if i can handle it would be 2 up my riba.
please all ur thoughts are needed.
wayne
think the .html got truncated in Jim's copy paste
http://www.hivandhepatitis.com/hep_c/news/2008/032808_b.html
http://www.hivandhepatitis.com/hep_c/news/2008/032808_b.html
As a Gt3a previous non-responder the above report really annoys me, and I believe it's high time they stopped putting Gt3 & 2 in the same box as it is becoming very apparent that the Gt2 results are skewing the numbers for Gt3.
Gt3 is harder to treat that originally thought and while that report may say there is no additional benefit to extending tx to 48 for 3s there IS a distinct trend to do just that now. What IS missing is good follow up data on these longer treatment times and studies that focus entirely on Gt3.
Perhaps that report is already outdated as weight based for Gt3 is also becoming SOC.
Btw, jmjm, I was unable to follow the 2nd link you posted, error 404, any ideas?
Gt3 is harder to treat that originally thought and while that report may say there is no additional benefit to extending tx to 48 for 3s there IS a distinct trend to do just that now. What IS missing is good follow up data on these longer treatment times and studies that focus entirely on Gt3.
Perhaps that report is already outdated as weight based for Gt3 is also becoming SOC.
Btw, jmjm, I was unable to follow the 2nd link you posted, error 404, any ideas?
Actually the new FDA label revisions is for the Pegintron, not Pegasys, they are a little different.
Jim, unless I am reading your link wrong, for geno2 or 3, this test does not prove
more than 800 riba flat rate dose is better for svr,
Please correct me if I am wrong.
Interesting that this WIN-R test is the largest test to date in the usa for hep c
"In the first report, Ira Jacobson and colleagues provided overall results for the 5,027 total participants enrolled in WIN-R.
Results
• Among patients with genotype 2 or 3, SVR rates were not significantly different depending on ribavirin dose (61.8% for weight-based and 59.5% for flat-dose), regardless of treatment duration.
• Among these patients, 48-week treatment was not superior to the standard 24-week course.
• Weight-based ribavirin was associated with larger reductions in hemoglobin levels.
• Other than hemoglobin reductions, safety profiles were similar across the ribavirin dose groups, including the 1400 mg/day group.
In conclusion, the study authors wrote, "Pegylated interferon alfa-2b plus weight-based ribavirin is more effective than flat-dose ribavirin, particularly in genotype 1 patients, providing equivalent efficacy across all weight groups."
They added that, "For genotype 2/3 patients, 24 weeks of treatment with flat-dose ribavirin is adequate; no evidence of additional benefit of extending treatment to 48 weeks was demonstrated."
Jim, unless I am reading your link wrong, for geno2 or 3, this test does not prove
more than 800 riba flat rate dose is better for svr,
Please correct me if I am wrong.
Interesting that this WIN-R test is the largest test to date in the usa for hep c
"In the first report, Ira Jacobson and colleagues provided overall results for the 5,027 total participants enrolled in WIN-R.
Results
• Among patients with genotype 2 or 3, SVR rates were not significantly different depending on ribavirin dose (61.8% for weight-based and 59.5% for flat-dose), regardless of treatment duration.
• Among these patients, 48-week treatment was not superior to the standard 24-week course.
• Weight-based ribavirin was associated with larger reductions in hemoglobin levels.
• Other than hemoglobin reductions, safety profiles were similar across the ribavirin dose groups, including the 1400 mg/day group.
In conclusion, the study authors wrote, "Pegylated interferon alfa-2b plus weight-based ribavirin is more effective than flat-dose ribavirin, particularly in genotype 1 patients, providing equivalent efficacy across all weight groups."
They added that, "For genotype 2/3 patients, 24 weeks of treatment with flat-dose ribavirin is adequate; no evidence of additional benefit of extending treatment to 48 weeks was demonstrated."
you are taking 17mg/kg if you would put up your dose to 1000mg that would be almost 21mg/kg... that would in my opinion be too high... and you have already cleared.
What genotype are you again? I forgot.
What genotype are you again? I forgot.
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
